VAM
SVA

Visium Asset Management’s Sinovac Biotech, Ltd SVA Stock Holding History

Visium Asset Management’s Portfolio SVA Stock Details SVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-1,000,000
Closed -$5.64M – 1402
2014
Q2 		$5.64M Hold
1,000,000
– – 0.09% 209
2014
Q1 		$7.2M Hold
1,000,000
– – 0.12% 171
2013
Q4 		$6.12M Hold
1,000,000
– – 0.12% 166
2013
Q3 		$5.98M Hold
1,000,000
– – 0.14% 124
2013
Q2 		$3.93M Buy
+1,000,000
New +$3.72M 0.09% 147

Other funds holding SVA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PRCM
Pine River Capital Management Minnetonka, Minnesota $32.9M AUM 4.47% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Visium Asset Management's SVA Position: Q3 2014 in Review

Visium Asset Management sold out of Sinovac Biotech, Ltd (SVA) in Q3 2014, closing a stake of 1,000,000 shares — an estimated $5.64M sold.

Visium Asset Management first reported a position in SVA in Q2 2013 and held it in 5 quarters. The position peaked at $7.2M in Q1 2014. 45 funds tracked by Wall St. Rank hold SVA as of Q3 2014.

  • Visium Asset Management reported no remaining Sinovac Biotech, Ltd position as of Q3 2014 after selling out during the quarter.
  • Visium Asset Management sold 1,000,000 Sinovac Biotech, Ltd shares in Q3 2014, an estimated $5.64M.
  • Visium Asset Management first reported a position in Sinovac Biotech, Ltd in Q2 2013 and held it in 5 quarters.
  • Visium Asset Management's Sinovac Biotech, Ltd position peaked at $7.2M in Q1 2014.
  • 45 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q3 2014.

Based on Visium Asset Management's 13F filing for Q3 2014, filed 14 Nov 2014.